Why bother?

The FDA says biogenerics, if approved, will be second class citizens:

FDA commissioner Dr. Andrew von Eschenbach told pharmaceutical executives such knockoffs would be considered only “similar” to brand-name drugs, which he later clarified to The Associated Press as meaning they would not be interchangeable or substitutable.

That definition mirrors that used by the European Medicines Agency, the FDA’s European counterpart.

Post-patent price regulation is a better solution.

March 16, 2007

Leave a Reply

Your email address will not be published. Required fields are marked *